Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Thymalin vs VIP (Vasoactive Intestinal Peptide)
An educational, source-based comparison of Thymalin and VIP (Vasoactive Intestinal Peptide) — how each peptide works, what it's researched for, and what to know before going deeper.
A polypeptide complex extracted from calf thymus, studied as an immune bioregulator. Research suggests restoration of T-cell function and thymic activity in aged and immunocompromised cohorts.
- Immunosenescence
- Recovery from infection in elderly cohorts
- Adjunct in chronic inflammatory conditions
- • Approved in Russia; not FDA-approved.
- • Mixture composition is not fully characterized.
Neuropeptide researched for immune modulation and lung protection.
A 28-amino-acid neuropeptide with broad immunomodulatory, anti-inflammatory, and bronchodilatory effects. Acts via VPAC1 and VPAC2 receptors to regulate T-cell function, macrophage polarization, and airway smooth muscle tone.
- Acute respiratory distress syndrome (ARDS)
- Chronic inflammatory conditions
- Autoimmune modulation
- Bronchial asthma and COPD
- • Short half-life limits therapeutic utility; analogs in development.
- • Not FDA-approved in native form.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Thymalin | Thymalin in geriatric patients: long-term outcomes | Advances in Gerontology | 2014 | Multi-year follow-up reported reduced morbidity and improved immune markers. |
| VIP (Vasoactive Intestinal Peptide) | VIP in acute respiratory distress syndrome | Critical Care Medicine | 2021 | Demonstrated lung-protective effects in preclinical ARDS models. |
| VIP (Vasoactive Intestinal Peptide) | VIP and immune tolerance | Frontiers in Immunology | 2019 | Reviewed mechanisms of T-regulatory cell induction and immune homeostasis. |
Side-effect & safety grid
- Approved in Russia; not FDA-approved.
- Mixture composition is not fully characterized.
- Short half-life limits therapeutic utility; analogs in development.
- Not FDA-approved in native form.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Thymalin vs VIP (Vasoactive Intestinal Peptide) — Key differences
- Class: Thymalin is classified as Immune · Bioregulator, while VIP (Vasoactive Intestinal Peptide) is Immune · Respiratory.
- Primary research focus: Thymalin — immunosenescence; VIP (Vasoactive Intestinal Peptide) — acute respiratory distress syndrome (ards).
- Tag: Immune · Longevity vs Immune · Respiratory.